Table 3.
Prognostic significance of selected genes in prostate cancer cohorts
| Swedish | Cambridge | Long | Taylor | TCGA | |
|---|---|---|---|---|---|
| TWIST1 |
2.05 (1.30–3.22) P = 0.0019 |
0.95 (0.39–2.35) P = 0.917 |
1.46 (0.84–2.54) P = 0.178 |
2.69 (1.11–6.49) P = 0.028 |
1.72 (1.13–2.60) P = 0.01 |
| KCNN2 |
2.39 (1.51–3.79) P = 0.000216 |
1.91 (0.75–4.86) P = 0.17 |
1.52 (0.87–2.27) P = 0.14 |
1.78 (0.78–4.08) P = 0.17 |
0.84 (0.56–1.26) P = 0.41 |
| SPRED1 | NA |
0.90 (0.36–2.23) P = 0.81 |
0.76 (0.44–1.32) P = 0.33 |
0.96 (0.43–2.13) P = 0.91 |
0.96 (0.64–1.44) P = 0.85 |
| PPFIBP2 | NA |
1.21 (0.49–3.02) P = 0.68 |
1.73 (0.99–3.03) P = 0.05 |
0.86 (0.38–1.92) P = 0.70 |
0.76 (0.50–1.13) P = 0.17 |
| JAG1 |
1.36 (0.88–2.10) P = 0.17 |
2.23 (0.85–5.88) P = 0.10 |
2.293 (1.28–4.12) P = 0.005 |
1.25 (0.56–2.80) P = 0.59 |
1.30 (0.87–1.94) P = 0.21 |
| IGFBP3 |
1.00 (0.65–1.55) P = 0.99 |
1.09 (0.44–2.68) P = 0.86 |
1.56 (0.89–2.73) P = 0.12 |
1.99 (0.85–4.66) P = 0.11 |
2.07 (1.36–3.20) P = 0.0008 |
| NDRG1 |
2.28 (1.43–3.64) P = 0.0005 |
1.43 (0.58–3.56) P = 0.44 |
0.81 (0.47–1.41) P = 0.45 |
0.78 (0.34–1.75) P = 0.54 |
0.96 (0.64–1.43) P = 0.82 |
BCR biochemical recurrence; OS overall survival; NA not applicable
Values are hazard ratios (95% confidence intervals). Cohorts were stratified by the median expression of each gene